{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"4"},{"groupId":"OG001","value":"13"}],"title":"Very good, good, and neither good nor bad"},{"measurements":[{"groupId":"OG000","value":"1"},{"groupId":"OG001","value":"5"}],"title":"Bad"},{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"1"}],"title":"Very bad"},{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"3"}],"title":"Unable to answer question"},{"measurements":[{"groupId":"OG000","value":"3"},{"groupId":"OG001","value":"10"}],"title":"Missing"}],"title":"Week 1"},{"categories":[{"measurements":[{"groupId":"OG000","value":"5"},{"groupId":"OG001","value":"18"}],"title":"Very good, good, and neither good nor bad"},{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"1"}],"title":"Bad"},{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"}],"title":"Very bad"},{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"2"}],"title":"Unable to answer question"},{"measurements":[{"groupId":"OG000","value":"3"},{"groupId":"OG001","value":"11"}],"title":"Missing"}],"title":"Week 5"}],"denoms":[{"counts":[{"groupId":"OG000","value":"8"},{"groupId":"OG001","value":"32"}],"units":"Participants"}],"description":"Participants who received the dabrafenib dispersible tablets for oral suspension completed a questionnaire to evaluate the palatability of the pediatric formulation. After taking the medication, participants provided feedback on the immediate reaction once the medication was placed into their mouth, rating their experience as very good, good, neither good nor bad, bad or very bad. The ratings of very good, good, and neither good nor bad were grouped together for reporting purposes.","groups":[{"description":"Participants in the HGG cohort received dabrafenib (orally, twice daily and dosed based on weight and age) and trametinib (orally, once daily in combination with the first daily dose of dabrafenib and dosed based on weight)","id":"OG000","title":"HGG Cohort: Dabrafenib and Trametinib"},{"description":"Participants in the LGG cohort randomized to receive dabrafenib (orally, twice daily and dosed based on weight and age) in combination with trametinib (orally, once daily in combination with the first daily dose of dabrafenib and was dosed based on weight)","id":"OG001","title":"LGG Cohort: Dabrafenib and Trametinib"}],"paramType":"COUNT_OF_PARTICIPANTS","populationDescription":"Participants who received at least one dose of dabrafenib as dispersible tablet for oral suspension and completed the palatability questionnaire for dabrafenib at week 1 or 5.","reportingStatus":"POSTED","timeFrame":"Week 1 and Week 5","title":"HGG and LGG Cohort: Palatability of Dabrafenib Oral Suspension Based on the Palatability Questionnaire Item: Immediate Reaction Once the Medication Was Placed Into the Mouth","type":"SECONDARY","unitOfMeasure":"Participants"}